Psychedelic Treatment for Adjustment Disorder in Cancer Patients with Greg Mayes Reunion Neuroscience and Dr. Manish Agrawal Sunstone Therapies TRANSCRIPT
Release Date: 03/24/2026
Building Foundational AI Infrastructure for Holistic View of Biology with Jean-Philippe Vert Bioptimus TRANSCRIPT
Empowered Patient Podcast
Jean-Philippe Vert, the Co-Founder and CEO of Bioptimus, is building a foundational AI model for biology to solve the problem of siloed biomedical research. Key goals are to bridge the translational gaps between drug discovery and development, and between clinical research and real-world patient outcomes, and to redesign clinical trials for greater efficiency and improved results. Creating digital twins of patients is a way to simulate treatment outcomes and create synthetic control arms for clinical trials, ultimately lowering the risk and cost of drug development and enabling the creation...
info_outline
Building Foundational AI Infrastructure for Holistic View of Biology with Jean-Philippe Vert Bioptimus
Empowered Patient Podcast
Jean-Philippe Vert, the Co-Founder and CEO of Bioptimus, is building a foundational AI model for biology to solve the problem of siloed biomedical research. Key goals are to bridge the translational gaps between drug discovery and development, and between clinical research and real-world patient outcomes, and to redesign clinical trials for greater efficiency and improved results. Creating digital twins of patients is a way to simulate treatment outcomes and create synthetic control arms for clinical trials, ultimately lowering the risk and cost of drug development and enabling the creation...
info_outline
Drug Targets Iron Dysregulation in Rare Neurodegenerative Disease Multiple System Atrophy with David Stamler Alterity Therapeutics TRANSCRIPT
Empowered Patient Podcast
David Stamler, CEO of Alterity Therapeutics, is developing a drug to treat multiple system atrophy (MSA), a rare and rapidly progressing neurodegenerative disease that often presents as Parkinson's disease but is distinct and more aggressive. There is no single genetic cause or specific biomarker, making accurate diagnosis a significant challenge. The lead drug is a novel small molecule designed to manage excess reactive iron in the brain, which drives the disease, and may be effective for other neurodegenerative diseases involving iron dysregulation. David explains, "Multiple system atrophy...
info_outline
Drug Targets Iron Dysregulation in Rare Neurodegenerative Disease Multiple System Atrophy with David Stamler Alterity Therapeutics
Empowered Patient Podcast
David Stamler, CEO of Alterity Therapeutics, is developing a drug to treat multiple system atrophy (MSA), a rare and rapidly progressing neurodegenerative disease that often presents as Parkinson's disease but is distinct and more aggressive. There is no single genetic cause or specific biomarker, making accurate diagnosis a significant challenge. The lead drug is a novel small molecule designed to manage excess reactive iron in the brain, which drives the disease, and may be effective for other neurodegenerative diseases involving iron dysregulation. David explains, "Multiple system atrophy...
info_outline
Psychedelic Treatment for Adjustment Disorder in Cancer Patients with Greg Mayes Reunion Neuroscience and Dr. Manish Agrawal Sunstone Therapies TRANSCRIPT
Empowered Patient Podcast
Greg Mayes, President and CEO of Reunion Neuroscience, and Dr. Manish Agrawal, the Co-Founder and CEO of Sunstone Therapies, shine a light on adjustment disorder, a disproportionate emotional or behavioral reaction to a significant life stressor such as a cancer diagnosis. This under-recognized condition lacks FDA-approved treatments and is often managed with SSRIs or talk therapy. The REKINDLE study evaluated the use of a psilocybin analog drug in development for treating adjustment disorder and has shown positive results by integrating emotional treatment into the standard of care for...
info_outline
Psychedelic Treatment for Adjustment Disorder in Cancer Patients with Greg Mayes Reunion Neuroscience and Dr. Manish Agrawal Sunstone Therapies
Empowered Patient Podcast
Greg Mayes, President and CEO of Reunion Neuroscience, and Dr. Manish Agrawal, the Co-Founder and CEO of Sunstone Therapies, shine a light on adjustment disorder, a disproportionate emotional or behavioral reaction to a significant life stressor such as a cancer diagnosis. This under-recognized condition lacks FDA-approved treatments and is often managed with SSRIs or talk therapy. The REKINDLE study evaluated the use of a psilocybin analog drug in development for treating adjustment disorder and has shown positive results by integrating emotional treatment into the standard of care for...
info_outline
Hospital Drug Diversion Detection and Prevention with Russ Nix and Dr. Stacey McCoy Wolters Kluwer Health TRANSCRIPT
Empowered Patient Podcast
Russ Nix, Consulting Associate Director, and Dr. Stacey McCoy, Pharmacy Clinical Program Manager for the Clinical Surveillance and Compliance business at Wolters Kluwer Health, highlight the problem of drug diversion in healthcare environments and the shared responsibility to prevent this breach. AI-enabled software is becoming crucial in detecting suspicious patterns, the types of individuals most likely to steal drugs, and gaps in the supply chain from ordering to delivering drugs to the patient. While opioids are the most commonly diverted drugs, motivated by substance abuse and addiction,...
info_outline
Hospital Drug Diversion Detection and Prevention with Russ Nix and Dr. Stacey McCoy Wolters Kluwer Health
Empowered Patient Podcast
Russ Nix, Consulting Associate Director, and Dr. Stacey McCoy, Pharmacy Clinical Program Manager for the Clinical Surveillance and Compliance business at Wolters Kluwer Health, highlight the problem of drug diversion in healthcare environments and the shared responsibility to prevent this breach. AI-enabled software is becoming crucial in detecting suspicious patterns, the types of individuals most likely to steal drugs, and gaps in the supply chain from ordering to delivering drugs to the patient. While opioids are the most commonly diverted drugs, motivated by substance abuse and addiction,...
info_outline
Advancing AI in Patient-Centered Blood Cancer Care with Meghan Gutierrez Lymphoma Research Foundation and Jennifer Branstetter BeOne Medicines TRANSCRIPT
Empowered Patient Podcast
Meghan Gutierrez, CEO of the Lymphoma Research Foundation, and Jennifer Branstetter, the Executive Director, North America Corporate Affairs at BeOne Medicines, join me to discuss the growing use of AI in patient care with a specific focus on individuals with lymphoma and other blood cancers. Emphasis is on the necessity of a collaborative, patient-centric approach to developing AI tools, bringing together patient advocacy organizations, healthcare professionals, and pharma partners to provide accurate information to patients. The goal is to serve a diverse population by providing...
info_outline
Advancing AI in Patient-Centered Blood Cancer Care with Meghan Gutierrez Lymphoma Research Foundation and Jennifer Branstetter BeOne Medicines
Empowered Patient Podcast
Meghan Gutierrez, CEO of the Lymphoma Research Foundation, and Jennifer Branstetter, the Executive Director, North America Corporate Affairs at BeOne Medicines, join me to discuss the growing use of AI in patient care with a specific focus on individuals with lymphoma and other blood cancers. Emphasis is on the necessity of a collaborative, patient-centric approach to developing AI tools, bringing together patient advocacy organizations, healthcare professionals, and pharma partners to provide accurate information to patients. The goal is to serve a diverse population by providing...
info_outlineGreg Mayes, President and CEO of Reunion Neuroscience, and Dr. Manish Agrawal, the Co-Founder and CEO of Sunstone Therapies, shine a light on adjustment disorder, a disproportionate emotional or behavioral reaction to a significant life stressor such as a cancer diagnosis. This under-recognized condition lacks FDA-approved treatments and is often managed with SSRIs or talk therapy. The REKINDLE study evaluated the use of a psilocybin analog drug in development for treating adjustment disorder and has shown positive results by integrating emotional treatment into the standard of care for serious illnesses.
Greg explains, "In fact, there are no approved investigational assets that had been approved by the FDA for adjustment disorder. But it was an area of exploration that the FDA encouraged us to move into in light of people's disproportionate and really unfortunate reactions in terms of a depressive or anxiolytic reaction to cancer diagnosis or other major medical illness like Parkinson's disease, MS, ALS, or pulmonary fibrosis."
Manish elaborates, "Well, usually you have to have had some stress-related event. For example, it could be things like divorce or job loss. But here, specifically, this study is targeting an illness, and the ones that Greg had just listed out, the neurologic conditions, as well as the cancer diagnosis. And then usually it leads to symptoms, intense feelings of sadness or anxiety or hopelessness. You can have a depressed mood with its subtypes with depressed mood. Some people have more anxiety. And so both a stressor and the symptoms that present are associated directly with that. So, for example, for the study, the symptoms of sadness need to be tied to the illness, such as cancer or MS."
#ReunionNeuroscience #SunstoneTherapies #AdjustmentDisorder #MentalHealth #REKINDLEStudy #Psychedelics #PsychedelicMedicine #CancerCare #MentalHealth #ClinicalTrials #Psilocybin #Oncology #PatientCare #MedicalInnovation #Neuroscience
